[Augmented indication field for Convulex therapy (author's transl)].
The therapeutic effect of n-dipropylacetate (DPA) is described in 20 patients with cerebral or spinal spasticity. Improvement was ween in 8 out of 11 patients with cerebral spasticity, 3 out of 5 patients with spinal spasticity and 3 out of 4 cases who had sustained perinatal damage. Satisfactory clinical amelioration and improvement in the EEG was observed in myoclonia, particularly of the Unverricht-Lundborg type.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002675:Child, Preschool; D004569:Electroencephalography; D004660:Encephalitis / Q000188:drug therapy; D005260:Female; D006429:Hemiplegia / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009128:Muscle Spasticity / Q000188:drug therapy*; D009207:Myoclonus / Q000188:drug therapy; D010264:Paraplegia / Q000188:drug therapy; D013036:Spasms, Infantile / Q000188:drug therapy; D014635:Valproic Acid / Q000627:therapeutic use
D014635:Valproic Acid
Zur Therapie mit Convulex in weitern Indikationsgebieten